Eton Pharmaceuticals (NASDAQ:ETON) Upgraded by B. Riley to “Strong-Buy” Rating

B. Riley upgraded shares of Eton Pharmaceuticals (NASDAQ:ETON) to a strong-buy rating in a research note issued to investors on Thursday morning,Zacks.com reports.

Several other research firms have also recently issued reports on ETON. Craig Hallum increased their target price on Eton Pharmaceuticals from $15.00 to $18.00 and gave the stock a “buy” rating in a research report on Wednesday. HC Wainwright increased their target price on Eton Pharmaceuticals from $15.00 to $17.00 and gave the stock a “buy” rating in a research note on Monday, January 6th.

Eton Pharmaceuticals Price Performance

ETON stock opened at $13.44 on Thursday. The stock’s fifty day moving average price is $11.64 and its 200-day moving average price is $7.35. The company has a market cap of $350.13 million, a P/E ratio of -61.09 and a beta of 1.38. Eton Pharmaceuticals has a 1 year low of $3.03 and a 1 year high of $15.00.

Institutional Investors Weigh In On Eton Pharmaceuticals

Several institutional investors have recently bought and sold shares of ETON. Westside Investment Management Inc. grew its holdings in Eton Pharmaceuticals by 5.7% in the 3rd quarter. Westside Investment Management Inc. now owns 618,675 shares of the company’s stock valued at $3,711,000 after buying an additional 33,275 shares in the last quarter. Geode Capital Management LLC increased its stake in Eton Pharmaceuticals by 13.5% during the 3rd quarter. Geode Capital Management LLC now owns 272,696 shares of the company’s stock worth $1,637,000 after buying an additional 32,365 shares during the period. Jane Street Group LLC purchased a new position in Eton Pharmaceuticals in the third quarter valued at $90,000. Parkman Healthcare Partners LLC lifted its stake in Eton Pharmaceuticals by 2.8% in the third quarter. Parkman Healthcare Partners LLC now owns 260,226 shares of the company’s stock worth $1,561,000 after acquiring an additional 7,029 shares during the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new position in Eton Pharmaceuticals in the third quarter valued at $54,000. 27.86% of the stock is currently owned by institutional investors and hedge funds.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.